We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Malarial Cytokine Responses Reduced by Age in Exposed Children

By LabMedica International staff writers
Posted on 10 Jan 2018
Elevated levels of pro-inflammatory cytokines and chemokines in the peripheral blood during acute malaria infection contribute to the control of parasitemia, but are also responsible for much of the immunopathology seen during symptomatic disease.

Young children are at greatest risk for malaria-associated morbidity and mortality. More...
The immune response of young children differs in fundamental ways from that of adults, and these differences likely contribute to the increased susceptibility of children to severe malaria and to their delayed development of immunity.

An international team of scientists working with those at University of California San Francisco (CA, USA) obtained blood samples from study cohort that was initiated in 2011 and is ongoing. This cohort consists of 100 households where malaria transmission in this region is holoendemic, with an annual entomological inoculation rate (EIR) of 310 infective bites per person year. In total, plasma samples from 48 children were analyzed: 25 from children 1 to 3 years old and 23 from children 7 to 10 years old.

Thick blood smears were stained with 2% Giemsa for 30 minutes. Thick smears were evaluated for the presence of parasitemia (asexual forms only) and gametocytes. The concentrations of 20 cytokines and chemokines were measured in plasma samples using Luminex technology. Fourteen cytokines and six chemokines were analyzed using a custom R&D Magnetic Luminex Screening Assay Human Premixed Multi-Analyte Kit and read on a Luminex MAGPIX CCD Imager. Human interferon gamma (IFNγ) OptEIA ELISA II Kits were used to quantify IFNγ levels in plasma.

The team found that younger children presenting with acute malaria exhibited much higher levels of tumor necrosis factor (TNF), interleukin-2 (IL2), and IL6, as well as increased T helper cells (Th1) associated chemokines interferon gamma-induced protein 10 (IP10), Monokine induced by gamma interferon (MIG), and monocyte chemoattractant protein-1 (MCP1), was compared to older children with acute malaria. Additionally, the regulatory cytokines IL10 and tumor necrosis factor receptor 1 (TNFRI) were dramatically elevated in younger children compared to older children during acute infection, indicating that regulatory as well as pro-inflammatory cytokine responses are dampened in later childhood.

The authors concluded that that despite age-related differences in immune responses, young children respond with a largely pro-inflammatory Th1-type cytokine and chemokine response, similar to naïve travelers; however, they also show increased levels of the regulatory cytokines IL10 and soluble TNFRI, which may limit their ability to develop robust immunity to subsequent malaria infections. The study was published on December 29, 2017, in the Malaria Journal.

Related Links:
University of California San Francisco


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.